Opioid Conversions

Pain Relief
Dependable Product Profile
Pharmacokinetic Profile
Flexible Dosing
Drug-Drug Interactions

Converting to Opana® ER from other oral opioids

Conversion ratios of oral opioids to Opana® ER1



Conversion from other oral opioids to OPANA® ER

While there are useful tables of oral and parenteral equivalents, there is substantial inter-patient variability in the relative potency of different opioid drugs and formulations. As such, it is safer to underestimate a patient’s 24-hour oral oxymorphone dose and provide rescue medication (e.g., immediate-release oxymorphone) than to overestimate the 24-hour oral oxymorphone dose and manage an adverse reaction. Consider the following general points:

In a Phase 3 clinical trial with an open-label titration period, patients were converted from their prior opioid to OPANA ER using the following table as a guide for the initial OPANA ER dose.

For example, a patient receiving oxycodone at a total daily dose of 40 mg would then be converted to a total daily dose of 20 mg of oxymorphone (40 mg x 0.5), dosed as OPANA ER 10 mg twice daily.

Patients 65 years of age or older, patients with mild hepatic impairment, and patients with moderate to severe renal impairment, have an increase in oxymorphone bioavailability. For these patients on prior opioid therapy, start at 50% of the starting dose for a younger patient or a patient with normal hepatic or renal function and titrate slowly.

All patients who are receiving long-acting opioid therapy should be monitored closely. It is imperative that the prescribers clinical judgment be utilized on each individual case.

Hcp Dosing Calc Button

References

  1. Opana® ER (Oxymorphone Hydrochloride) Extended-Release Tablets CII [Prescribing Information]. Endo Pharmaceuticals. Chadds Ford, PA; 2012.
  2. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. May 2002;23(5):355-368.